This multicentre, double-blind, randomized study compared the pharmacokinetics of itraconazole given at 200 mg once daily for 3 months and intermittently at 200 mg twice daily for 1 week per month followed by a 3-week drug-free period for 3 months in the treatment of onychomycosis. Patients were followed for 9 months after treatment. Itraconazole and hydroxy-itraconazole plasma concentrations and itraconazole nail tip concentrations were determined at regular intervals. With intermittent therapy (n ¼ 64), increases of consistent magnitude were seen in the mean itraconazole and hydroxy-itraconazole plasma concentrations at the end of each 1-week treatment phase; values returned towards baseline during each subsequent 3-week drug-free period. The mean concentration of itraconazole in fingernail tips increased steadily from week 4, reached a maximum value at week 24 (213 ng/g), declined sharply between weeks 24 and 36 and returned to baseline by week 48; the mean concentration profile was similar for toenail tips (maximum value 305 ng/g at week 24) but decreased at a slower rate. With continuous therapy (n ¼ 65), steady-state mean plasma concentrations of itraconazole and hydroxy-itraconazole were obtained within 4-5 weeks of the start of treatment and remained reasonably constant between weeks 4 and 12. The mean concentration of itraconazole in fingernail tips reached a maximum value at week 12 (524 ng/g) and returned towards baseline by week 48; in contrast, the maximum mean concentration of itraconazole in toenail tips was 698 ng/g at week 36 and did not return to baseline by week 48. No clear relationship was observed between response to treatment and concentration of itraconazole or hydroxyitraconazole in plasma or itraconazole in nails, suggesting that concentrations exceeded therapeutic levels. In conclusion, intermittent therapy resulted in higher maximum itraconazole plasma concentrations but lower total drug exposure, and hence lower itraconazole nail concentrations, than continuous therapy. However, the intermittent schedule was not associated with a lower cure rate, which indicates that itraconazole nail concentrations remained within the therapeutic range.
Onychomycosis, an infection of the nail caused by any fungus, including dermatophytes, yeasts and moulds, most often manifests as the distal subungual type, 1 with the fungus usually invading the distal nail bed and possibly proceeding proximally in the nail bed or to the nail plate. Fungal nail infections are chronic and recalcitrant to treatment [2] [3] [4] and, as such, present a particular therapeutic challenge. Research has therefore been focused on the development of new, improved antifungal agents for the treatment of onychomycosis. Itraconazole is a triazole-derived oral antifungal agent with a broad spectrum of antifungal activity in vitro and in vivo, encompassing dermatophytes, yeasts and moulds. [5] [6] [7] [8] [9] [10] [11] Itraconazole has strong lipophilic properties and a high affinity for keratinized tissue. 12, 13 Nail matrix kinetics have revealed that itraconazole can be found in the distal part of the fingernail within 1 week of the start of therapy with 100 mg of itraconazole daily, which suggests that itraconazole penetrates the nail not only through the nail matrix but also through the nail bed. 12, 14 In addition, therapeutic concentrations of itraconazole have been shown to persist in fingernails for 3 months after treatment and in toenails for up to 6 months after treatment. 15 Itraconazole concentrations detected in finger and toenail tips with itraconazole 200 mg daily for 3 months were 10 times higher than those detected with itraconazole 100 mg daily for 3 months and were associated with a better outcome.
The results of these pharmacokinetic studies led to the suggestion that continuous therapy with itraconazole 200 mg daily for 3 months might not be necessary to maintain therapeutic levels of itraconazole in the nail. As a result, a new concept in the treatment of onychomycosis has emerged, namely intermittent therapy with itraconazole 200 mg twice daily for 1 week per month, followed by a 3-week drug-free period, for 3 months. This novel intermittent itraconazole dosing schedule has been compared with the conventional continuous itraconazole regimen in a multicentre, double-blind, randomized, parallel-group, phase III trial; results from the efficacy and safety evaluation (reported previously) 16 showed that the schedules were similarly safe, well tolerated and effective in the treatment of onychomycosis. Here, we present the results of assessments performed to investigate the pharmacokinetics of itraconazole during continuous and intermittent dosing.
Patients and methods

Patients
Patients were randomized to continuous therapy with itraconazole 200 mg daily for 3 months or intermittent therapy with itraconazole 200 mg twice daily for the first week of each month followed by a 3-week drug-free period for 3 months. Patients also received placebo capsules to maintain double-blind conditions. In both groups, the 3-month treatment phase was followed by a 9-month drug-free follow-up period.
Men and women aged 18-60 years with distal subungual onychomycosis of the toenails, confirmed by microscopy and positive culture for a dermatophyte, were included in the study. The involvement of at least 30% of the surface of one toenail was also required. Concurrent onychomycosis of the fingernails or a fungal lesion of the pilose or glabrous skin, or both, were optional. Patients were excluded if moulds or Candida species were cultured in the nail samples or if the patients had received systemic antifungal therapy within the 6 months or topical antifungal therapy within the 2 weeks before the start of the trial. Concurrent use of other systemic or topical antifungal therapies, local corticosteroids, digoxin, oral anticoagulants, terfenadine, cyclosporin A, H 2 -receptor antagonists, cisapride, simvastatin or lovastatin, midazolam or triazolam, oral hypoglycaemic agents or enzymeinducing drugs, such as rifampicin and phenytoin, was not permitted. Patients were also excluded if they had psoriasis, abnormal liver function or a serious disease that might prevent completion of the trial. Women were excluded if they were possibly pregnant or lactating. The trial was performed in accordance with the Declaration of Helsinki and its revisions. Ethics committee approval was obtained, and patients gave their informed consent to participate.
Bioanalysis
Venous blood samples of 10 mL were collected at the start of the study and at weeks 1, 4, 5, 8, 9 and 12 to determine itraconazole and hydroxy-itraconazole plasma concentrations using high-performance liquid chromatography (HPLC). 17 Hydroxy-itraconazole, the main metabolite of itraconazole, has similar in vitro antifungal activity to itraconazole and may contribute significantly to in vivo antifungal activity. 13 The lower limit of quantification was 10 ng/mL for both compounds.
Distal nail clippings were collected from toenails and fingernails at the start of the study and at weeks 4, 8, 12, 24, 36 and 48 to determine itraconazole nail tip concentrations using HPLC. 17 The lower limit of quantification for itraconazole in nails was a 2·0 ng/sample. Nails with entire distal parts missing or destroyed (including the target toenail, which was used for the mycological examination) were excluded. Mean concentration-time curves were constructed for itraconazole in plasma and nails, and for hydroxy-itraconazole in plasma, for both treatment schedules. No formal pharmacokinetic parameters could be derived from these curves, because they were constructed from too few sample points.
Statistical analysis
The treatment groups were compared at baseline using the Mann-Whitney U-test for age, weight and height and the chi-squared test for sex. Blood sampling was not always performed at the prescribed time points, so time intervals were constructed around each time point. The boundaries of these time intervals are given in Table 1 . Descriptive statistics were calculated for each treatment group and time interval for itraconazole and hydroxyitraconazole concentrations in plasma and for itraconazole concentrations in finger and toenails. A subgroup analysis was performed for responders and non-responders; response was defined as at least markedly improved in the overall evaluation at the end of the follow-up period. 16 
Results
Patient characteristics and disposition
Of the 129 patients recruited to the study, 65 patients were assigned to continuous therapy and 64 patients were assigned to intermittent therapy. No clinically relevant differences were found between the treatment groups in terms of patient and disease characteristics at baseline. 16 During the 3-month, double-blind treatment phase, one patient in the continuous therapy group and three patients in the intermittent therapy group withdrew because of adverse events. During the 9-month, drug-free, follow-up period, one patient withdrew from the continuous therapy group because of abnormal laboratory values and one patient withdrew from each treatment group because of insufficient response. In addition, a protocol deviation was noted in one patient in each treatment group; these patients failed to meet the selection criteria because they were culture negative for a dermatophyte at the start of the trial.
Plasma concentration-time profiles
Mean plasma concentration-time data for itraconazole and hydroxy-itraconazole for the two dosing schedules are presented in Figure 1 . With the intermittent schedule, increases of consistent magnitude were seen in the mean itraconazole and hydroxy-itraconazole plasma concentrations at the end of each 1-week treatment phase (weeks 1, 5 and 9; mean ranges 1130-1416 ng/ mL and 2061-2402 ng/mL, respectively). By the end of each 3-week drug-free period (weeks 4, 8 and 12), the mean plasma concentrations of both itraconazole and hydroxy-itraconazole had returned towards baseline values in most patients. With the continuous schedule, plasma steady-state levels of itraconazole and hydroxyitraconazole were obtained within 4-5 weeks of the start of treatment. The mean plasma concentrations of both compounds remained reasonably constant between weeks 4 and 12, ranging from 842 to 992 ng/mL for itraconazole and from 1446 to 1706 ng/mL for hydroxy-itraconazole. 
Nail tip concentration-time profiles
Mean finger and toenail tip concentration-time values for itraconazole for the two dosing schedules are presented in Table 2 . Intermittent therapy resulted in a steady increase in the mean itraconazole concentration in fingernail tips from 59 ng/g to 213 ng/g between weeks 0 and 24. Between weeks 24 and 36, the concentration of itraconazole in fingernails declined sharply and, by week 48, had returned to baseline values in all patients. Intermittent therapy produced a similar itraconazole concentration profile in toenails, with a maximum mean concentration of 305 ng/g at week 24. However, the decrease in the itraconazole concentration was slower in toenail tips than in fingernail tips. Continuous therapy resulted in a maximum mean itraconazole concentration of 524 ng/g in the fingernail tips after 12 weeks of therapy. In almost all patients, itraconazole concentrations in the fingernails returned towards baseline values within 36 weeks after the end of continuous therapy (week 48). In contrast, in the toenails, continuous therapy produced a maximum mean itraconazole concentration of 698 ng/g at week 36, which did not return towards baseline by week 48.
Concentration-response relationships
In the group of patients receiving intermittent therapy, plasma concentrations of itraconazole (Fig. 2) and hydroxy-itraconazole (data not shown) tended to be higher in responders than in non-responders, but no such difference was observed in patients receiving continuous therapy. Conversely, in the group receiving continuous therapy, responders had higher itraconazole concentrations in finger and toenails than nonresponders, but this difference was not seen in the intermittent therapy group (data not shown). Neither difference was statistically significant.
Discussion
In the present study, 3 months of intermittent therapy with itraconazole 200 mg twice daily for 1 week followed by a 3-week drug-free period resulted in higher maximum itraconazole plasma concentrations but lower total systemic exposure to itraconazole than 3 months of continuous treatment with itraconazole 200 mg once daily. This lower systemic exposure was reflected in the lower concentrations of itraconazole observed in nails with intermittent therapy than with continuous therapy. In general, the rate of decrease in itraconazole concentration after the end of treatment was slower in toenails than in fingernails, probably because of the slower growth rate of toenails than of fingernails.
No clear relationship could be observed between plasma concentrations of itraconazole or hydroxyitraconazole, or nail concentrations of itraconazole, and response to therapy. However, the efficacy and safety evaluation indicated that both dosing schedules were effective in the treatment of onychomycosis, with a trend for efficacy in favour of the intermittent schedule. 16 The fact that the intermittent schedule was not associated with a lower cure rate indicates that nail concentrations remained within the therapeutic range, despite the lower total systemic exposure to itraconazole and hydroxy-itraconazole. Moreover, the minimum inhibitory concentration of itraconazole for most dermatophytes and Candida species correlates with 100 ng/g nail keratin. 18 The mean nail concentrations for both intermittent and continuous therapies in the present study were at or above this level for most measurements during the treatment phase and 12 weeks into the follow-up phase.
The total itraconazole dose given in the intermittent schedule is half that given in the continuous schedule. This reduction in total drug intake may be beneficial in reducing side-effects and improving cost-effectiveness. In an economic evaluation of antifungal agents in the treatment of toenail onychomycosis, the itraconazole 1-week intermittent schedule yielded a more favourable average cost-effectiveness ratio than the conventional continuous itraconazole schedule. 19 In addition, the duration of active treatment is reduced with the intermittent schedule, which may also help to improve safety and to promote patient compliance; indeed, treatment duration has recently been identified as the critical factor in determining patient preference for treatment schedules for onychomycosis. 20 In conclusion, the results of the present pharmacokinetic assessment show that the 1-week intermittent itraconazole dosing schedule produces higher maximum itraconazole plasma concentrations but lower total drug exposure and hence lower itraconazole nail tip concentrations than the continuous itraconazole dosing schedule. However, the lack of a lower cure rate with the intermittent schedule indicates that itraconazole nail concentrations remained within the therapeutic range. 
